NRIX Nurix Therapeutics
- 16.080
- +1.130+7.56%
Nurix Therapeutics News
Stifel: Maintains Nurix Therapeutics (NRIX.US) rating, adjusted from buy to buy rating, target price $27.00.
Stifel: Maintains Nurix Therapeutics (NRIX.US) rating, adjusted from buy to buy rating, target price $27.00.
Stifel Maintains Buy on Nurix Therapeutics, Maintains $27 Price Target
Stifel analyst Stephen Willey maintains Nurix Therapeutics with a Buy and maintains $27 price target.
Stifel Nicolaus Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price Target
Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $31 price target.
Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Nurix Therapeutics (NRIX)
Nurix Therapeutics Announces Upcoming Oral Presentation of New Data From Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on therapy in CLL patients including patients with resistance mutations
Nurix Therapeutics Initiated at Overweight by Stephens & Co.
Nurix Therapeutics Initiated at Overweight by Stephens & Co.
Nurix Therapeutics (NRIX.US) was first covered by Stephens & Co. with an incremental rating, with a target price of $20.00.
Nurix Therapeutics (NRIX.US) was first covered by Stephens & Co. with an incremental rating, with a target price of $20.00.
Stephens & Co. Initiates Coverage On Nurix Therapeutics With Overweight Rating, Announces Price Target of $20
Stephens & Co. analyst Sudan Loganathan initiates coverage on Nurix Therapeutics with a Overweight rating and announces Price Target of $20.
Nurix Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 42.76% Stephens & Co. → $20 Initiates Coverage On → Overweight 04/11/2024 64.17% RBC Capital $2
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pat
Nurix Therapeutics(NRIX.US) Officer Sells US$44,878.17 in Common Stock
$Nurix Therapeutics(NRIX.US)$ Officer van Houte Hans sold 3,499 shares of common stock on May 2, 2024 at an average price of $12.826 for a total value of $44,878.17.Source: Announcement What is statem
Analysts' Top Healthcare Picks: Evolent Health (EVH), Nurix Therapeutics (NRIX)
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Nurix Therapeutics (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which includes 1,750,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock.
Nurix Therapeutics (NASDAQ:NRIX) Climbs Higher After Beating Expectations
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of JPMorgan Chase & Co. (NYSE:JPM) fell sharply during Friday's session following first-quarter earnings. Net revenue (managed) of $42.5 billion (+8% Y/Y), beating the consensus of $41.8 billi
Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler
Nurix Therapeutics Shares Are Trading Lower After the Company Priced an Upsized Public Offering of 10,166,667 Shares of Common Stock at $15 per Share.
Nurix Therapeutics Shares Are Trading Lower After the Company Priced an Upsized Public Offering of 10,166,667 Shares of Common Stock at $15 per Share.
Sector Update: Health Care Stocks Steady Pre-Bell Friday
Health care stocks were steady premarket Friday, with the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) both inactive. Nurix Therapeutics (NRIX) stock was down more tha
Sector Update: Health Care
Health care stocks were steady premarket Friday, with the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) both inactive. Nurix Therapeutics (NRIX) stock was down nearly 5
Analysis
Price Target
No Data
